Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director Declaration

2 Jul 2025 07:00

RNS Number : 3814P
Oxford Biomedica PLC
02 July 2025
 

 

 

 

OXB Directorship notification under UK Listing Rule 6.4.9R(2)

Oxford, UK - 2 July 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Mr. Colin Bond, Independent Non-Executive Director, has been appointed as Additional Director (Non-Executive, Independent) of OneSource Specialty Pharma Limited, a company listed at the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE), subject to the approval of the shareholders by way of special resolution expected to be announced on or around 1 August 2025.

 

-Ends-

 

Enquiries:

 

OXB

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNRTMATMTIMMRA
Date   Source Headline
1st Oct 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSInterim Results for 6 months ended 30 June 2025
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20253:36 pmRNSPDMR Dealings
21st Aug 202510:24 amRNSHolding(s) in Company
20th Aug 20257:00 amRNSAdmission of Shares and Total Voting Rights
15th Aug 20251:45 pmRNSPDMR Dealings
15th Aug 20257:05 amRNSResults of Placing
14th Aug 20255:02 pmRNSProposed Placing of New Ordinary Shares
1st Aug 20257:00 amRNSOXB Secures New Loan Facility with Oaktree
1st Aug 20257:00 amRNSTotal Voting Rights
28th Jul 20257:00 amRNSHalf Year Trading Update
2nd Jul 20257:00 amRNSDirector Declaration
1st Jul 20257:00 amRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTotal Voting Rights
23rd Jun 20257:00 amRNSOXB completes acquisition of US subsidiary
17th Jun 20256:00 pmRNSDirector/PDMR Shareholding
11th Jun 20256:02 pmRNSResult of Annual General Meeting
11th Jun 20257:02 amRNSAGM Update
10th Jun 202510:49 amRNSHolding(s) in Company
5th Jun 20257:00 amRNSBlock Listing Application
3rd Jun 20257:00 amRNS-ROXB Launches Advisory Board
2nd Jun 20257:00 amRNSTotal Voting Rights
16th May 20255:52 pmRNSGrant of options
1st May 20257:00 amRNSTotal Voting Rights
30th Apr 20254:49 pmRNSPerson Closely Associated Dealing
29th Apr 20256:14 pmRNSHolding(s) in Company
28th Apr 20251:00 pmRNS2025 Annual General Meeting notification
23rd Apr 20255:45 pmRNSHolding(s) in Company
9th Apr 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
4th Apr 20258:52 amRNSHolding(s) in Company
1st Apr 20257:00 amRNSOXB Total Voting Rights
27th Mar 20254:45 pmRNSDirector Declaration
3rd Mar 20259:00 amRNSTotal Voting Rights
26th Feb 20257:00 amRNS-ROXB to present at Leerink Conference
20th Feb 20253:42 pmRNSHolding(s) in Company
20th Feb 20251:32 pmRNS-ROXB Lentiviral Vectors Used in Gene Therapy Trial
20th Feb 20251:13 pmRNSStandard form for notification of major holdings
17th Feb 20257:00 amRNSFull Year Trading Update and Notice of Results
5th Feb 20257:00 amRNSAppointment of New Joint Corporate Broker
3rd Feb 20257:00 amRNSTotal Voting Rights
23rd Jan 202511:07 amRNSBlock Listing Application
16th Jan 20254:23 pmRNSHolding(s) in Company
16th Jan 20254:20 pmRNSHolding(s) in Company
15th Jan 20254:30 pmRNSHolding(s) in Company
2nd Jan 20257:00 amRNSBlock Listing Return
2nd Jan 20257:00 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTotal Voting Rights
22nd Nov 20242:56 pmRNSGrant of options
18th Nov 20247:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.